Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Matteo Pirro"'
Publikováno v:
Seminars in Cancer Biology. 69:337-348
Despite considerable advances in the application of liposomal drug delivery systems in cancer treatment, the clinical application of liposomal formulations has been limited by many factors. It seems that there is a wide gap between results of experim
Autor:
Vanessa Bianconi, Arrigo F G Cicero, Matteo Pirro, Amirhossein Sahebkar, Petri T. Kovanen, Mohammad Mohajeri
Publikováno v:
Pharmacology & Therapeutics. 199:91-110
Mast cells are tissue-resident cells, which have been proposed to participate in various inflammatory diseases, among them the cardiovascular diseases (CVDs). For mast cells to be able to contribute to an inflammatory process, they need to be activat
Autor:
Maciej Banach, Amirhossein Sahebkar, Vanessa Bianconi, Željko Reiner, Armita Mahdavi Gorabi, Saeideh Hajighasemi, Hossein Ahmadi Tafti, Matteo Pirro
Publikováno v:
Pharmacological Research. 143:119-132
Familial hypercholesterolemia (FH) is a genetic autosomal dominant disorder caused by an impaired receptor-mediated low-density lipoprotein (LDL) removal from the circulation, mainly due to disruptive autosomal co-dominant mutations in the LDL recept
Autor:
Paolo Puccetti, Rita Chiari, Francesca Fallarino, Vanessa Bianconi, Biagio Ricciuti, Giulia Costanza Leonardi, Amirhossein Sahebkar, Matteo Pirro, Sara Baglivo
Publikováno v:
Pharmacology & Therapeutics. 196:105-116
Immunotherapy through immune checkpoint blockers (ICBs) is quickly transforming cancer treatment by improving patients' outcomes. However, innate and acquired resistance to ICBs remain a major challenge in clinical settings. Indoleamine 2,3-dioxygena
PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?
Autor:
Maria Corina Serban, Vanessa Bianconi, Maciej Banach, Massimo Raffaele Mannarino, Amirhossein Sahebkar, Matteo Pirro
Publikováno v:
Journal of Clinical Lipidology. 12:1123-1132
The serine protease proprotein convertase subtilisin/kexin type 9 (PCSK9) modulates the levels of low-density lipoprotein cholesterol and cardiovascular risk. Potential risks of adverse neurological effects of intensive lipid-lowering treatment have
Publikováno v:
Seminars in cancer biology. 73
An inverse correlation between high-density lipoprotein cholesterol (HDL-C) and cancer risk has been shown by several epidemiological studies. Some studies have even suggested that HDL-C can be used as a prognostic marker in patients with certain typ
Autor:
Sajad Chamani, Aida Tasbandi, Tannaz Jamialahmadi, Amirhossein Sahebkar, Matteo Pirro, George E. Barreto, Vanessa Bianconi
Publikováno v:
Mediators of Inflammation, Vol 2020 (2020)
Mediators of Inflammation
Mediators of Inflammation
Acute inflammation has been described as a reactive dynamic process, promoted by the secretion of proinflammatory mediators, including lipid molecules like leukotrienes and prostaglandins, and counterbalanced by proresolving mediators including omega
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4384d7bd06513d5039c650d67853feda
Autor:
Daniel J. Rader, Maciej Banach, Amirhossein Sahebkar, Alberico L. Catapano, Biagio Ricciuti, Matteo Pirro
Publikováno v:
Progress in Lipid Research. 71:54-69
The relationship between high-density lipoproteins (HDLs), HDL-cholesterol (HDLC) and cancer incidence and mortality is controversial. Although most studies conducted so far, including well-designed prospective studies and meta-analyses, have reveale
Autor:
Paolo Calabrò, Francesco Bagaglia, Matteo Pirro, Petri T. Kovanen, Vanessa Bianconi, Giuseppe Patti, Biagio Ricciuti, Amirhossein Sahebkar
Publikováno v:
Pharmacology & Therapeutics. 181:156-168
Stem cells have the potential to differentiate into cardiovascular cell lineages and to stimulate tissue regeneration in a paracrine/autocrine manner; thus, they have been extensively studied as candidate cell sources for cardiovascular regeneration.
Publikováno v:
Drug Discovery Today. 22:883-895
Diabetes mellitus (DM) is associated with an increased risk of cardiovascular disease (CVD). Inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) have emerged as effective low-density lipoprotein cholesterol-lowering compounds. Althoug